A Randomized, Controlled, Double-blind, Multicenter Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
This study aims to evaluate the efficacy of Adebrelimab plus concurrent chemoradiotherapy compared with placebo plus concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer by evaluating progression-free survival (PFS).
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Participate in the study voluntarily, sign the informed consent form.
• Subjects were able to provide primary or metastatic cancer samples.
• At least one measurable lesion.
• Expected survival \> 3 months.
• ECOG 0 \
• With adequate organ functions.
Locations
Other Locations
China
Fudan University Shanghai Cancer Center
RECRUITING
Shanghai
Contact Information
Primary
Xiaoxu Zhang
xiaoxu.zhang@hengrui.com
+86-0518-82342973
Backup
Zhaoyu Zhong
zhaoyu.zhong.zz8@hengrui.com
+86-0518-82342973
Time Frame
Start Date: 2025-10-17
Estimated Completion Date: 2028-12
Participants
Target number of participants: 720
Treatments
Experimental: SHR-1316 Group
Placebo_comparator: SHR-1316 Placebo Group
Related Therapeutic Areas
Sponsors
Leads: Shanghai Shengdi Pharmaceutical Co., Ltd